MrinalMGounderMD

Cancer Genetics/Cancer Risk Assessment, Sarcoma, Clinical Pharmacology

Associate Professor, Memorial Sloan Kettering Cancer Center

Overview of Dr. Gounder

Dr. Mrinal Gounder is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from SUNY Upstate Medical University and has been in practice 13 years. He specializes in cancer genetics/cancer risk assessment, sarcoma, and clinical pharmacology. He has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(276) 345-0636

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2004 - 2007
SUNY Upstate Medical UniversityClass of 2004

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2008 - 2025
NC State Medical License 2020 - 2022
IL State Medical License 2004 - 2008

Clinical Trials

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Start of enrollment: 2010 Jun 01
Completed
Phase 1, Phase 2
Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jun 20
Completed
Phase 1
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Start of enrollment: 2013 Oct 01
Completed
Phase 1
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Start of enrollment: 2014 Mar 21
Completed
Phase 3
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) Start of enrollment: 2018 May 21
Recruiting
Phase 1
Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 Start of enrollment: 2018 Jul 15
Completed
Phase 1
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) Start of enrollment: 2019 Jun 11
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.
Sujana Movva, Kenneth Seier, Viswatej Avutu, Lauren B Banks, Jason Chan
Clinical Cancer Research. 2024-12-16
A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik
Clinical Cancer Research. 2024-12-11
Epigenetic Therapy in a Rare Ovarian Cancer - A Double-Edged Sword.
Charles Hsu, Jason A Konner, Mrinal M Gounder
The New England Journal of Medicine. 2024-08-22

Lectures

Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Why Cancer Clinical Trials with More Indians Gives Hope to PatientsAugust 16th, 2024

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment